Xichun Hu
YOU?
Author Swipe
View article: HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer Open
Purpose The HER2CLIMB-05 study ( ClinicalTrials.gov identifier: NCT05132582 ) is investigating the efficacy and safety of adding tucatinib to trastuzumab and pertuzumab as first-line (1L) maintenance therapy in patients with human epiderma…
View article: Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial
Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial Open
Background Combination of HER2-targeted therapy and endocrine therapy offers a more tolerable alternative to HER2-targeted chemotherapy regimens for estrogen receptor (ER)-positive, HER2-positive advanced breast cancer (ABC), but with comp…
View article: Potential regulatory role of the m<sup>6</sup>A-lncRNA axis in breast cancer: molecular mechanisms and therapeutic implications
Potential regulatory role of the m<sup>6</sup>A-lncRNA axis in breast cancer: molecular mechanisms and therapeutic implications Open
N6-methyladenosine (m 6A) modification, the most prevalent internal modification in eukaryotic messenger RNAs (mRNAs), has emerged as a crucial regulator of various biological processes. This reversible epigenetic modification is dynamical…
View article: Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06 Open
For patients with HER2 IHC 0 mBC, rescoring and/or retesting with the Roche HER2 4B5 assay is encouraged to determine eligibility for T-DXd.
View article: Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine
Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine Open
Cancer of unknown primary (CUP), a set of histologically confirmed metastases that cannot be identified or traced back to its primary despite comprehensive investigations, accounts for 2–5% of all malignancies. CUP is the fourth leading ca…
View article: A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors Open
This study demonstrated the equivalent efficacy and safety of LY01011 to denosumab in patients with BM.
View article: Patient-reported quality of life in Asian patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the PALOMA-4 trial
Patient-reported quality of life in Asian patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the PALOMA-4 trial Open
Background: Palbociclib plus an aromatase inhibitor is approved for treatment of patients with ER+/HER2− advanced breast cancer (ABC). In the PALOMA-4 trial, adding palbociclib to letrozole prolonged median progression-free survival in Asi…
View article: Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison
Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison Open
The outcomes in this MAIC study including Asian patients with ROS1-positive NSCLC showed a trend for greater clinical benefit with entrectinib versus crizotinib. These findings may contribute to better-informed treatment decisions.
View article: Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2− advanced breast cancer: Final results of the randomized phase III MONARCH plus trial
Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2− advanced breast cancer: Final results of the randomized phase III MONARCH plus trial Open
Background: In the interim analysis of MONARCH plus, adding abemaciclib to endocrine therapy (ET) improved progression-free survival (PFS) and objective response rate (ORR) in predominantly Chinese postmenopausal women with HR+/HER2− advan…
View article: OR98 UPDATED OVERALL SURVIVAL (OS) OUTCOMES FROM THE PHASE 3 PHOEBE TRIAL OF PYROTINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER
OR98 UPDATED OVERALL SURVIVAL (OS) OUTCOMES FROM THE PHASE 3 PHOEBE TRIAL OF PYROTINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER Open
Results: Interestingly, in subgroup analysis of rs1045642 in ABCB1 gene, a significant difference was found with a greater progression free survival (PFS) of the AA homozygous group compared to the heterozygous alleles ( p = 0.002, with Bo…
View article: Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor
Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor Open
Background Patients with HER2-positive metastatic breast cancer (MBC) are at high risk of developing central nervous system (CNS) metastases. A potent and selective HER2 inhibitor with good blood–brain barrier (BBB) penetration is highly d…
View article: Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer Open
Capivasertib-fulvestrant therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone among patients with hormone receptor-positive advanced breast cancer whose disease had progressed during or a…
View article: Supplementary Figure from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
Supplementary Figure from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study Open
Supplementary Figure from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
View article: Supplementary Data from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
Supplementary Data from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study Open
Supplementary Data from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
View article: Supplementary Figure from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
Supplementary Figure from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study Open
Supplementary Figure from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
View article: Supplementary Figure from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
Supplementary Figure from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study Open
Supplementary Figure from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
View article: Supplementary Data from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
Supplementary Data from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study Open
Supplementary Data from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study